Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work ...
Harbour BioMed announced its wholly owned subsidiary is exercising a warrant agreement to acquire common stock in Spruce ...
Texas Biomed expanding work — and revenue base — with Big Pharma; seen as key to its competitiveness
Before the COVID-19 pandemic, Texas Biomedical Research Institute had established itself as a go-to researcher of infectious diseases, along with therapeutics and vaccines to combat them. It was ...
Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "The Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries Training Course (Mar 11th - Mar 12th, 2026)" training has been added to ...
Traditionally, medtech companies have utilized a sales-based model, but many of them are now transitioning to recurring-revenue models like subscription-based services or device-as-a-service. The need ...
Current Pharmaceutical Analysis (CPA) is a distinguished journal in the field of pharmaceutical and biomedical analysis. Published by Far Publishing Company, CPA provides a platform for researchers to ...
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies ...
New Haven, Conn.-based Yale University is partnering with pharmaceutical company Boehringer Ingelheim to launch a Biomedical Data Science Fellowship program aimed at innovating drug discovery. A May ...
The sodium alginate market offers opportunities in food, pharma, and biomed sectors due to its natural, non-toxic appeal. Consumer trends toward sustainable materials, advancements in green technology ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Canadian life sciences company Ondine Biomedical has appointed Dr. Simon Sinclair as Chief Medical Officer, as the Company prepares to start the US Phase ...
Lifecore Biomedical shares rose after the company said it signed a master services agreement with a large pharmaceutical customer. The stock rose 12% to $8.62 on Wednesday. Shares are up 16% this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback